210 related articles for article (PubMed ID: 33617328)
21. [CCAFU french national guidelines 2016-2018 on testicular germ cell tumors].
Durand X; Fléchon A; Murez T; Rocher L; Camparo P; Morel-Journel N; Savoie PH; Ferretti L; Sèbe P; Méjean A
Prog Urol; 2016 Nov; 27 Suppl 1():S147-S165. PubMed ID: 27846929
[TBL] [Abstract][Full Text] [Related]
22. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.
Gels ME; Marrink J; Visser P; Sleijfer DT; Droste JH; Hoekstra HJ; Andrews PW; Schraffordt Koops H
Ann Surg Oncol; 1997 Jun; 4(4):321-7. PubMed ID: 9181232
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
Divrik RT; Akdoğan B; Ozen H; Zorlu F
J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
[TBL] [Abstract][Full Text] [Related]
24. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.
Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ
Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479
[TBL] [Abstract][Full Text] [Related]
25. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
[TBL] [Abstract][Full Text] [Related]
26. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis.
Pizzocaro G; Zanoni F; Salvioni R; Milani A; Piva L; Pilotti S
J Urol; 1987 Dec; 138(6):1393-6. PubMed ID: 2824862
[TBL] [Abstract][Full Text] [Related]
27. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
28. Surveillance in patients with stage I testicular nonseminomatous germ cell tumors.
Gez E; Wygoda M; Nussbaum N; Figer A; Gil RI; Inbal M
Cancer Invest; 1993; 11(1):10-4. PubMed ID: 8380748
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
[TBL] [Abstract][Full Text] [Related]
30. Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: late relapse may occur.
Boyer MJ; Cox K; Tattersall MH; Findlay MP; Grygiel J; Rogers J
Urology; 1997 Oct; 50(4):588-92. PubMed ID: 9338737
[TBL] [Abstract][Full Text] [Related]
31. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
Swanson DA
Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
[No Abstract] [Full Text] [Related]
32. Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later.
Riedinger CB; Labbate C; Werntz RP; Eggener SE
Urology; 2018 Dec; 122():16-18. PubMed ID: 30170087
[No Abstract] [Full Text] [Related]
33. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
34. Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option.
Hamilton RJ; Jewett MAS; Warde P; Hansen A
Eur Urol Focus; 2019 Sep; 5(5):702-703. PubMed ID: 31129064
[TBL] [Abstract][Full Text] [Related]
35. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
36. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
Fonseca A; Xia C; Lorenzo AJ; Krailo M; Olson TA; Pashankar F; Malogolowkin MH; Amatruda JF; Billmire DF; Rodriguez-Galindo C; Frazier AL; Shaikh F
J Clin Oncol; 2019 Feb; 37(5):396-402. PubMed ID: 30576269
[TBL] [Abstract][Full Text] [Related]
37. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center.
Nicolai N; Tarabelloni N; Gasperoni F; Catanzaro M; Stagni S; Torelli T; Tesone A; Bettin L; Necchi A; Giannatempo P; Raggi D; Colecchia M; Piva L; Salvioni R; Paganoni AM; Pizzocaro G; Biasoni D
J Urol; 2018 Mar; 199(3):741-747. PubMed ID: 28964782
[TBL] [Abstract][Full Text] [Related]
38. [The role of tumour markers in diagnosis and management of testicular germ cell tumours].
Krege S; Albers P; Heidenreich A
Urologe A; 2011 Mar; 50(3):313-21. PubMed ID: 21327901
[TBL] [Abstract][Full Text] [Related]
39. Value of tumor markers in nonseminomatous germ cell tumor of the testis.
Kulkarni JN; Kamat MR
Eur Urol; 1993; 24(2):166-71. PubMed ID: 7690705
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
Keskin S; Ekenel M; Başaran M; Bavbek S
Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
